Perkinelmer INC: management transactions · United States · SEC (Form 4)

About Perkinelmer INC

PerkinElmer Inc. (ticker PKI) is a United States-based company listed on the NYSE/NASDAQ market, with headquarters in Shelton, Connecticut, United States. The group is a long-established provider of scientific, analytical, and specialized service solutions for research, diagnostics, and regulated industrial workflows. PerkinElmer highlights nearly 90 years of innovation history, positioning itself as a global operator in discovery, measurement, testing, and lab services rather than as a broad diversified healthcare conglomerate. ([perkinelmer.com](https://www.perkinelmer.com/about-us?utm_source=openai)) From an equity analyst perspective, the investment case rests on a specialized and recurring-demand model. PerkinElmer serves laboratories, pharmaceutical and biotech customers, and food and applied markets with tools and services that support sample preparation, analytical measurement, workflow optimization, and GMP-related operations. The company emphasizes a large installed base of more than 100,000 active instruments, around 90,000 customers, offices in 35 countries, and reach into 168 countries through direct operations and distributors. That footprint gives PerkinElmer meaningful global scale in a niche segment, while keeping the business model focused and technically differentiated. ([perkinelmer.com](https://www.perkinelmer.com/about-us?utm_source=openai)) Its offering spans analytical instruments, sample preparation technologies, laboratory services, and end-to-end support for scientific and manufacturing workflows. Key branded platforms and service lines include OneSource, Project Farma, and Covaris. Covaris, a PerkinElmer company, is specifically associated with sample preparation technologies for life sciences research and molecular diagnostics. This mix is important because it shows that PerkinElmer competes not only on hardware, but also on workflow integration, service depth, and customer lock-in through installed equipment, consumables, and support contracts. ([perkinelmer.com](https://www.perkinelmer.com/about-us?utm_source=openai)) In competitive terms, PerkinElmer occupies a defensible position in markets where product performance, compliance, and technical support matter more than price alone. Its exposure to pharmaceutical, life sciences, and food testing applications provides a relatively resilient demand profile, as these end markets are tied to quality control, regulation, and ongoing R&D activity. The company’s value proposition is therefore anchored in technical credibility, application expertise, and global service reach. ([perkinelmer.com](https://www.perkinelmer.com/about-us?utm_source=openai)) Recent corporate updates reinforce that strategy. PerkinElmer announced the opening of a new facility in High Wycombe, the United Kingdom, aimed at improving customer support and strengthening R&D capability across its global value chain. The company also unveiled new products such as the Avio 3000 ICP-OES and the Clarus Nova GC, signaling continued product innovation in analytical instrumentation. For investors tracking SEC Form 4 insider transactions, these developments suggest an ongoing emphasis on portfolio refresh, international expansion, and operational execution. ([perkinelmer.com](https://www.perkinelmer.com/corporate-and-newsroom/perkinElmer-opens-new-uk-facility-in-high-wycombe?utm_source=openai))